BioGaia AB Expands Horizons with New Subsidiary

In a strategic move to broaden its research and innovation capabilities, BioGaia AB, a prominent player in the health care biotechnology sector, has announced the launch of a new subsidiary, BioGaia New Sciences AB. This development, reported on July 16, 2025, marks a significant expansion beyond the company’s core operations, which have traditionally focused on pediatric and adult health through probiotic products.

BioGaia AB, listed on the Swedish Stock Exchange, has been a leader in the biotechnology industry since its establishment in 1990. The company is renowned for its probiotic solutions aimed at addressing various health concerns, including infantile colic, gastrointestinal issues, and oral health problems. With a market capitalization of 10.58 billion SEK and a close price of 103.7 SEK as of May 29, 2025, BioGaia has demonstrated robust financial performance, despite fluctuations in its stock price over the past year.

The creation of BioGaia New Sciences AB signifies the company’s commitment to exploring new frontiers in microbiome research. This subsidiary will focus on areas beyond BioGaia’s traditional scope, with an initial emphasis on skin health. Maik Lepatey, CEO of BioGaia New Sciences, highlighted the potential of leveraging probiotics to revolutionize skincare by drawing parallels between the microbiomes of the skin and the gut. “With the power of probiotics, a deep commitment to science-driven results, and innovation, we have a fantastic opportunity to redefine skincare to be based on both health and care,” Lepatey stated.

This strategic expansion aligns with BioGaia’s long-standing dedication to health and wellness, extending its expertise into new domains. By tapping into the burgeoning field of microbiome research, BioGaia aims to develop microbiome-friendly and biotika-containing products that could transform the skincare industry.

As BioGaia New Sciences AB embarks on this exciting journey, stakeholders and industry observers will be keenly watching its progress. The company’s ability to innovate and adapt to emerging health trends will be crucial in maintaining its leadership position in the biotechnology sector.

For more information on BioGaia’s initiatives and products, visit their website at www.biogaia.com .